article thumbnail

EMA’s psychedelic workshop leaves stakeholders with as many questions as answers

Agency IQ

By Sebastian Godoy, MPH Earlier this year, the EMA hosted a multi-stakeholder workshop to discuss regulatory issues surrounding drug development of psychedelic products. EMA has now published a report on the workshop. Fill out the form to read the full article.

article thumbnail

Upcoming EveryLife Foundation Scientific Workshop on May 21, 2024 will Address Challenges in Developing Therapies for Ultra-Rare Diseases

FDA Law Blog: Drug Discovery

By Sarah Wicks — On May 21, 2024, the EveryLife Foundation for Rare Diseases (ELF) will host a Scientific Workshop at the National Press Club in Washington, D.C. aimed at identifying and characterizing the challenges in developing therapies for ultra-rare diseases and conditions that affect exceedingly small populations.

Disease 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Workshop addresses oncology dose optimization across full span of development

Agency IQ

BY CHELSEY MCINTYRE, PHARMD , KARI OAKES In a series of broad-ranging, frank discussions, attendees at a joint FDA-American Association of Cancer Research (AACR) workshop worked through opportunities and challenges for dose optimization across the span of cancer drug development activities.

FDA 59
article thumbnail

Perficient to Host Workshop at B2B Connect

Perficient: Drug Development

From June 10-12, B2B Connect will be in San Diego, and Perficient will be hosting a workshop entitled “How to Prioritize Your Direct-to-Consumer Capabilities: What Should I Do Now vs. Next?” If you want to attend the show and our workshop, register at the B2B Connect site.

article thumbnail

Perficient’s Sitecore Personalize Decision Model Workshop

Perficient: Drug Development

In this half day workshop, we’ll work with your team to identify opportunities for optimization and create models that employ the stages, offers and conditions approach to creating a conceptual model for personalization. Interested in learning more? Reach out to me on LinkedIn , Twitter or fill out our contact form.

article thumbnail

Analysis Life Sciences Thank You Workshop addresses oncology dose optimization across full span of development

Agency IQ

Workshop addresses oncology dose optimization across full span of development In a series of broad-ranging, frank discussions, attendees at a joint FDA-American Association of Cancer Research (AACR) workshop worked through opportunities and challenges for dose optimization across the span of cancer drug development activities.

Science 40
article thumbnail

More than Just Words: Prioritizing Patient-Centered Drug Development

LifeSciVC

By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC Patients and their care partners are at the center of our work in the life sciences industry – but at what point during the drug development process should companies start to engage these key stakeholders?